Favorable outcomes and FDG-PET changes following tocilizumab treatment for febrile infection-related epilepsy syndrome in a child.

MLA

Wan, Lin, et al. “Favorable Outcomes and FDG-PET Changes Following Tocilizumab Treatment for Febrile Infection-Related Epilepsy Syndrome in a Child.” International Immunopharmacology, vol. 146, Jan. 2025, p. 113872. EBSCOhost, https://doi.org/10.1016/j.intimp.2024.113872.

APA

Wan, L., Liu, J., Wang, J., Zhu, L., Wang, W., Li, S., Wang, R., & Yang, G. (2025). Favorable outcomes and FDG-PET changes following tocilizumab treatment for febrile infection-related epilepsy syndrome in a child. International Immunopharmacology, 146, 113872. https://doi.org/10.1016/j.intimp.2024.113872

Chicago

Wan, Lin, Jiajin Liu, Jing Wang, Liang Zhu, Wen Wang, Siwen Li, Ruimin Wang, and Guang Yang. 2025. “Favorable Outcomes and FDG-PET Changes Following Tocilizumab Treatment for Febrile Infection-Related Epilepsy Syndrome in a Child.” International Immunopharmacology 146 (January): 113872. doi:10.1016/j.intimp.2024.113872.